Us Bancorp \De\ Stoke Therapeutics, Inc. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 114 shares of STOK stock, worth $924. This represents 0.0% of its overall portfolio holdings.

Number of Shares

114

Previous 184 38.04%

Holding current value

$924

Previous $2,000 50.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	SELL	$10.8 - $13.92 $756 - $974	-70 Reduced 38.04%	114 $1,000
Q3 2024 Oct 28, 2024	SELL	$12.24 - $15.92 $2,594 - $3,375	-212 Reduced 53.54%	184 $2,000
Q2 2024 Aug 06, 2024	BUY	$11.03 - $17.52 $4,367 - $6,937	396 New	396 $5,000
Q3 2023 Nov 03, 2023	SELL	$3.78 - $11.99 $1,069 - $3,393	-283 Reduced 34.47%	538 $2,000
Q2 2023 Aug 09, 2023	SELL	$7.93 - $13.82 $634 - $1,105	-80 Reduced 8.88%	821 $8,000
Q1 2023 May 09, 2023	BUY	$7.65 - $10.38 $3,136 - $4,255	410 Added 83.5%	901 $7,000
Q4 2022 Feb 13, 2023	SELL	$7.07 - $15.69 $6,674 - $14,811	-944 Reduced 65.78%	491 $4,000
Q3 2022 Oct 27, 2022	SELL	$12.56 - $22.53 $992 - $1,779	-79 Reduced 5.22%	1,435 $18,000
Q2 2022 Aug 01, 2022	BUY	$10.36 - $23.93 $11,924 - $27,543	1,151 Added 317.08%	1,514 $20,000
Q1 2022 May 11, 2022	BUY	$17.19 - $26.1 $4,159 - $6,316	242 Added 200.0%	363 $8,000
Q4 2021 Feb 11, 2022	BUY	$18.11 - $30.72 $2,191 - $3,717	121 New	121 $3,000
Q4 2020 Feb 04, 2021	SELL	$33.62 - $61.93 $20,172 - $37,158	-600 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$16.8 - $34.15 $10,080 - $20,490	600 New	600 $14,000

Others Institutions Holding STOK

# of Institutions

136

Shares Held

57.3M

Call Options Held

5.7K

Put Options Held

24.4K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $320M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account